retatrutide commercial name brand Retatrutide, a new weight loss drug not available on the market yet, is Retatrutide 10mg Triple Agonist |

Results from a Cleveland Clinic review A retrospective chart review from Cleveland Clinic identified 161 patients (mean body mass index 35 8 kg/m2 ) who had a documented history of pancreatitis and then had recurrent acute pancreatitis after being prescribed a GLP-1 receptor agonist

however, studies have shown that it may be associated with weight loss in individuals with type 2 diabetes

For GLP-1 users looking to support their protein and electrolyte intake, Arrae Clear Protein+ offers a convenient way to address both

This guide walks through the full TRIUMPH program, the TRIUMPH-4 dataset, the 2026 readouts still to come, how retatrutide stacks up against tirzepatide and semaglutide on published trial data, and what the regulatory picture realistically looks like from here

Any chest pain, heart palpitations, or cardiovascular symptoms